Why Drug Delivery Is the New Power Move

Halozyme, BrYet, and Merus push drug delivery from niche science to a central force in modern medicine

21 Nov 2025

Drug delivery technologies are moving closer to the centre of biotech strategy, as new research and corporate initiatives point to rising interest in tools that make medicines easier and faster to administer. Recent developments from Halozyme, BrYet and Merus reflect growing momentum behind platforms that promise more precise or more convenient dosing.

A new study has reinforced this shift by showing how quickly novel delivery systems can progress from early research to clinical testing. The report cites increasing pressure on developers to convert laboratory concepts into products that meet patient expectations for targeted and less burdensome therapies. Researchers said this demand is speeding investment cycles and influencing development priorities across the sector.

Halozyme has been expanding its work on technology that converts lengthy intravenous infusions into rapid injections given under the skin. The company said delivery design is becoming a significant factor in treatment uptake, particularly as healthcare providers look for ways to reduce clinic time and improve patient experience.

BrYet reported an expansion of patent protection for its targeted cancer delivery platform, which seeks to direct therapies more accurately to diseased tissue. The company’s scientific team said the field is approaching a point where long-standing assumptions about how drugs move through the body can be reassessed, supporting the development of more refined delivery pathways.

Merus added to the activity through a developing partnership with Halozyme focused on delivery improvements for its antibody programmes. Analysts said the collaboration indicates how drug makers are now treating delivery as a strategic differentiator rather than a downstream technical step.

The companies still face hurdles, including the need to scale manufacturing, secure regulatory approvals and demonstrate consistent performance in clinical and real-world settings. Industry executives view these tasks as signs of a sector expanding quickly rather than obstacles likely to slow progress.

With investment rising and research programmes broadening, drug delivery is emerging as a central area of competition within biotech. Developers expect the field to influence how future treatments are designed, evaluated and used, as companies position themselves for a market that places greater value on practical and patient-centred delivery options.